Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2022 Results assessing biomarker levels using serum samples of ankylosing spondylitis patients from following clinical studies: NCT02437162, NCT02438787, NCT0315828 and NCT02349061 presented at the 23rd Annual Congress of the European League Against Rheumatism
01 Dec 2021 Results assessing long-term efficacy and safety of ustekinumab through 2 years in patients with active systemic lupus erythematosus (SLE) published in The Journal of Rheumatology
03 Oct 2020 Results assessing Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels, published in the Arthritis and Rheumatology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com